CTOs on the Move

Counsyl

www.counsyl.com

 
Counsyl is a DNA testing and genetic counseling service that offers genetic screening for men, women and their children. Our philosophy is simple - focus on diseases where advanced knowledge makes a difference in health outcomes, whether it`s changing a behavior, pursuing preventative measures, or simply preparing for what lies ahead. Counsyl has screened over 750,000 patients and served over 10,000 health professionals in its modern clinical laboratory. From the purely mechanical to profoundly human, Counsyl strives to make genetic screening truly accessible to everyone. The team consists of world class engineers, scientists and clinical experts as well as a ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.counsyl.com
  • 180 Kimball Way
    South San Francisco, CA USA 94080
  • Phone: 888.268.6795

Executives

Name Title Contact Details

Funding

Counsyl raised $80M on 11/06/2017

Similar Companies

Kerby Centre

Kerby Centre is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bedford Public Library

The Communitys front porch...for learning, for leisure, for life! www.bedfordlibrary.org | This page is not open to citizen postings & is not to be used as notification to the City of an emergency. Please contact 9-1-1 in the case of an emergency.

Ameritox Ltd

Ameritox is the nation's leader in pain prescription monitoring. Only Ameritox offers RxGuardian, the most thorough and personalized lab report available.

PanOptica

At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.